Skip to main content
Steven Hamilton, an R&D scientist in the HPC Methods for Nuclear Applications group at ORNL, leads the ExaSMR project. ExaSMR was developed to run on the Oak Ridge Leadership Computing Facility’s exascale-class supercomputer, Frontier. Credit: Genevieve Martin/ORNL, U.S. Dept. of Energy

The Exascale Small Modular Reactor effort, or ExaSMR, is a software stack developed over seven years under the Department of Energy’s Exascale Computing Project to produce the highest-resolution simulations of nuclear reactor systems to date. Now, ExaSMR has been nominated for a 2023 Gordon Bell Prize by the Association for Computing Machinery and is one of six finalists for the annual award, which honors outstanding achievements in high-performance computing from a variety of scientific domains.  

Cadet Elyse Wages, Mike Shaffer and Amanda Sandifer pose with a collected sample of air. Credit: Liz Neunsinger/ORNL, U.S. Dept. of Energy

Cadet Elyse Wages, a rising junior at the United States Air Force Academy, visited ORNL with one goal in mind: collect air.

The DEMAND single crystal diffractometer at the High Flux Isotope Reactor, or HFIR, is the latest neutron instrument at the Department of Energy’s Oak Ridge National Laboratory to be equipped with machine learning-assisted software, called ReTIA. Credit: Jeremy Rumsey/ORNL, U.S. Dept. of Energy

Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.

oxygen isotope 28

Rare isotope oxygen-28 has been determined to be "barely unbound" by experiments led by researchers at the Tokyo Institute of Technology and by computer simulations conducted at ORNL. The findings from this first-ever observation of 28O answer a longstanding question in nuclear physics: can you get bound isotopes in a very neutron-rich region of the nuclear chart, where instability and radioactivity are the norm? 

Madhavi Martin portrait image

Madhavi Martin brings a physicist’s tools and perspective to biological and environmental research at the Department of Energy’s Oak Ridge National Laboratory, supporting advances in bioenergy, soil carbon storage and environmental monitoring, and even helping solve a murder mystery.

Rose Montgomery

Rose Montgomery, a distinguished researcher and leader of the Used Fuel and Nuclear Material Disposition group at ORNL, has been selected to participate in the U.S. WIN Nuclear Executives of Tomorrow, or NEXT, class of 2023 to 2024.

The OpeN-AM experimental platform, installed at the VULCAN instrument, features a robotic arm that prints layers of molten metal to create complex shapes. Credit: Jill Hemman/ORNL, U.S Dept. of Energy

Technologies developed by researchers at ORNL have received six 2023 R&D 100 Awards.  

A beam of excited sodium-32 nuclei implants in the FRIB Decay Station initiator is used to detect decay signatures of isotopes. Credit: Gary Hollenhead, Toby King and Adam Malin/ORNL, U.S. Dept. of Energy

Timothy Gray of ORNL led a study that may have revealed an unexpected change in the shape of an atomic nucleus. The surprise finding could affect our understanding of what holds nuclei together, how protons and neutrons interact and how elements form.

Group of young kids sitting at a lab table.

A group at the Department of Energy's Oak Ridge National Laboratory made a difference for local youth through hands-on projects that connected neutron science and engineering intuitively.

Neutron experiments helped reveal the one-carbon enzymatic mechanism that synthesizes vital food sources for cancer cells that depend on vitamin B6, providing key insights into designing novel drugs to slow the spread of aggressive cancers. Credit: Jill Hemman/ORNL, U.S. Dept. of Energy

After a highly lauded research campaign that successfully redesigned a hepatitis C drug into one of the leading drug treatments for COVID-19, scientists at ORNL are now turning their drug design approach toward cancer.